{"classes":[{"categories":[{"measurements":[{"comment":"The value is not estimable.","groupId":"OG000","lowerLimit":"0.73","upperLimit":"NA","value":"2.64"},{"comment":"These values are not estimable because no event happened yet.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with MRD status negative at day 100 (post-AHCT). They have MRD negative or positve at EOI.","id":"OG000","title":"MRD Negative at Day 100"},{"description":"Patients with MRD status stay positive at both EOI and day 100.","id":"OG001","title":"MRD Status Positive at Day 100 (Post-AHCT)"}],"paramType":"MEDIAN","populationDescription":"Patients with MRD status information at the EOI and day 100 (post-AHCT).","reportingStatus":"POSTED","timeFrame":"up to 7 years","title":"Progression Free Survival by MRD Status at Day 100.","type":"SECONDARY","unitOfMeasure":"years"}